- Semaglutide-based drugs (e.g., Ozempic, Wegovy) are now linked to a rare but irreversible eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. The European Medicines Agency (EMA) confirmed a doubled risk for Type 2 diabetes patients.
- A safety review by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) found a clear association between semaglutide and NAION. Drug labels will be updated to reflect this risk.
- Novo Nordisk, the maker of these drugs, will comply with the EMA’s recommendations but maintains that benefits outweigh risks, arguing no definitive proof links semaglutide to NAION. Critics accuse slow action on safety concerns.
- Semaglutide drugs are highly profitable but face competition and scrutiny, echoing past cases where blockbuster drugs (e.g., Vioxx, Paxil) later revealed severe risks.
- The EMA advises users with sudden vision changes to seek immediate medical care and consider discontinuing semaglutide if NAION is diagnosed. Global regulators, including the FDA, may reassess safety profiles.
(Natural News)—A blockbuster class of weight-loss and diabetes drugs – including Ozempic, Wegovy and Rybelsus – now carries a newly confirmed risk: sudden blindness.
The European Medicines Agency (EMA) announced Friday, June 6, that semaglutide – the active ingredient in these medications – increases the likelihood of a rare but devastating eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). The finding, based on a months-long safety review, adds to growing concerns about the long-term effects of drugs that have been hailed as medical breakthroughs.
NAION is a condition caused by insufficient blood flow to the optic nerve, the critical structure that transmits visual signals from the eye to the brain. When the nerve is damaged, vision loss can occur suddenly – often without warning. It is the second-leading cause of optic nerve blindness, trailing only glaucoma.
The EMA’s review found that adults with Type 2 diabetes taking semaglutide face twice the risk of developing NAION compared to those not on the drug. While classified as a “very rare” side effect affecting up to 1 in 10,000 users, the irreversible nature of the condition makes it alarming. (Related: Ozempic and Wegovy linked to increased risk of BLINDNESS again in new study, raising alarms among doctors.)
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) launched its investigation in January 2025, scrutinizing clinical trial data, real-world patient reports and medical studies. Given the discovery, thee agency now recommends updating drug labels to reflect this risk – a move that could influence prescribing habits worldwide.
Novo Nordisk responds to EMA’s findings
Novo Nordisk, the Danish pharmaceutical giant behind these drugs, has stated it will comply with the EMA’s request. However, it maintains that the benefits still outweigh the risks.
The company insists that neither clinical trials nor post-market surveillance definitively prove semaglutide causes NAION. However, critics argue that regulators and manufacturers have been slow to address mounting safety concerns, including earlier investigations into suicidal thoughts and kidney cancer risks tied to these medications.
Semaglutide-based drugs have revolutionized obesity and diabetes treatment, generating billions in revenue for Novo Nordisk. But the company has faced turbulence, including the ousting of its CEO in May amid investor fears of losing dominance in the booming weight-loss drug market. Competitors like Eli Lilly’s Zepbound are gaining ground, while patients and doctors now grapple with balancing rapid weight loss against potentially life-altering side effects.
This is not the first time blockbuster drugs have faced scrutiny after widespread adoption. Painkillers like Vioxx and antidepressants such as Paxil were initially celebrated before later being linked to severe cardiovascular risks and suicidal ideation, respectively.
The EMA advises users experiencing sudden vision changes to seek immediate medical attention and consider discontinuing semaglutide if NAION is diagnosed. While the absolute risk remains low, the irreversible damage makes this a critical consideration – especially for those with preexisting eye conditions.
The EMA’s decision could pressure other regulators, including the U.S. Food and Drug Administration (FDA), to revisit semaglutide’s safety profile. The FDA has not announced a similar review as of writing, but past precedents suggest international findings often trigger American action. For millions relying on semaglutide for diabetes or weight management, the EMA’s warning is a sobering reminder: No drug is without risk.
DangerousMedicine.com has more similar stories. Watch Jefferey Jaxen and Del Bigtree discussing the dangerous side of Ozempic in this clip.
More related stories:
- The dark truth behind Ozempic and Wegovy: Big Pharma’s profit-driven gamble with your health.
- The hidden dangers of using weight loss medications like Wegovy and Mounjaro.
- CDC: Weight-loss drugs linked to thousands of hospital visits, life-threatening side effects.
Sources include:
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.